Steven Cook Sells 23,263 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 23,263 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $22.76, for a total value of $529,465.88. Following the transaction, the chief financial officer directly owned 187,209 shares of the company’s stock, valued at $4,260,876.84. This represents a 11.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Omada Health Stock Up 2.5%

NASDAQ:OMDA opened at $23.55 on Friday. The business’s 50-day moving average price is $18.01 and its 200 day moving average price is $15.33. Omada Health, Inc. has a 52-week low of $10.28 and a 52-week high of $26.92. The firm has a market cap of $1.40 billion and a P/E ratio of -87.22.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $78.05 million during the quarter. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. Sell-side analysts expect that Omada Health, Inc. will post -0.01 EPS for the current year.

Institutional Investors Weigh In On Omada Health

Several hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC acquired a new stake in Omada Health during the 2nd quarter worth about $637,000. Walleye Capital LLC acquired a new position in shares of Omada Health in the 2nd quarter valued at about $458,000. Ilex Capital Partners UK LLP purchased a new stake in shares of Omada Health in the second quarter worth approximately $201,000. Soros Fund Management LLC acquired a new stake in shares of Omada Health during the second quarter worth approximately $640,000. Finally, Raymond James Financial Inc. purchased a new position in Omada Health during the second quarter valued at approximately $32,000.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. The Goldman Sachs Group restated a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Wells Fargo & Company increased their price objective on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. reduced their price objective on Omada Health from $32.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, March 12th. Citizens Jmp lifted their target price on Omada Health from $18.00 to $21.00 and gave the stock a “market outperform” rating in a report on Friday, May 8th. Finally, Barclays boosted their target price on Omada Health from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Omada Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.91.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.